FOXP1-GINS1轴促进DLBCL的扩散,并指导多克索鲁比辛的耐药性
Zhenfa Chen1, Ting Wang1, Cui Li1
1Key Laboratory of Developmental Genes and Human Disease in Ministry of Education, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Biochemistry and Molecular Biology, Medical School of Southeast University, Nanjing 210009, China.
Journal of Cancer
|August 14, 2023
概括
在扩散性大B细胞淋巴瘤 (DLBCL) 中,FOXP1-GINS1轴被上调,促进癌症生长和对多克索鲁比辛的抗性. 针对这一轴为DLBCL治疗提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 过度表达GINS1与各种癌症的不良结果有关,但其在扩散性大B细胞淋巴瘤 (DLBCL) 中的作用未得到充分研究.
- 了解DLBCL中的GINS1调节和功能对于开发向疗法至关重要.
研究的目的:
- 研究GINS1在扩散性大B细胞淋巴瘤 (DLBCL) 中的表达,调节和功能意义.
- 探索针对FOXP1-GINS1轴作为DLBCL治疗策略的潜力.
主要方法:
- 对临床DLBCL标本和细胞系的分析.
- 电泳运动转移试验 (EMSA),染色体免疫沉 (ChIP) 和光酶记者试验用于确定基因调节.
- 活体异种移植小鼠模型,CCK8细胞增殖试验和殖民地形成试验,以评估功能作用.
主要成果:
- 在DLBCL组织和细胞系中,GINS1的高调显著.
- FOXP1直接与GINS1促进体结合,通过转录激活其表达.
- 高GINS1表达与FOXP1水平相关,并与淋巴瘤细胞中多克索鲁比抗性有关.
结论:
- 调节FOXP1-GINS1轴在DLBCL病原和化学抵抗中起着至关重要的作用.
- 针对FOXP1-GINS1轴为DLBCL治疗提供了一个有希望的治疗途径.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K


